Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. He is a full Professor of Virology in Vienna and ...
Prof. Walter H. Gunzburg is the co-founder, Chairman of the Board and Chief Technical Officer of Austrianova. He is a full Professor of Virology in Vienna and has had many years of experience in the biotech industry. As scientific advisor to the international vaccine company, Bavarian Nordic, from 1994-2001, he was involved in their IPO. He has also been a scientific advisor to the German biotech companies, Paktis and Liponova, as well as the U.S. biotech company, Tocagen Inc, all of which developed/are developing advanced medicinal treatments for cancer. Dr. Gunzburg was also the Director of the Christian Doppler Laboratory for Gene Therapeutic Vector Development. Currently, he is a board member of ViruSure, a virus and prion testing company located in Vienna that he cofounded.
Dr. Gunzburg has been actively involved in European ethics and regulatory affairs in the fields of cell and gene therapy, as well as xenotransplantation, for many years where he was a member of the German Medical Association's Central Commission for Somatic Gene Therapy and a Faculty member of the European Academy for the Study of the Consequences of Scientific and Technological Advance. He continues to be an active researcher and has published more than 130 peer-reviewed scientific publications and co-authored the first German language textbook on gene therapy, as well as being a member of the editorial board of a number of international cell and gene therapy journals including Trends in Molecular Medicine.
SG Austria (operating under Austrianova Singapore Pte Ltd) conducts feasibility studies and development work for companies and research groups on the encapsulation of living cells in cellulose sulphate using its proprietary cell-in-a-box technology. The main focus is on areas of biotechnology, healthcare, research and probiotics but the technology has wide applications in other areas such as agriculture, environmental, cosmetics and veterinary medicine. The company is located in Singapore’s top research Biotech hub, Biopolis
Austrianova is a high tech, life science and biotech company with a global footprint that encapsulates living cells in bio-inert polymers.
The Cell-in-a-Box™ technology, developed by Austrianova, is a means to protect, isolate, store and transport living cells.
The proprietary technology can be used for a variety of purposes.
In healthcare, it facilitates the safe implantation of cells, holding them isolated from the immune system and allowing long term production of therapeutic molecules in patients.
In biotechnology, the Cell-in-a-Box™ technology protects cells in bioreactors and fermenters, while at the same time simplifying purification of bioproducts produced from the cells and reducing production cost.
The technology can also be applied to probiotics, cosmetics and agriculture, environmental protection and monitoring, as well as forming the basis of a powerful research tool.
The company’s proprietary cell packaging material, Gel8, used for the Cell-in-a-Box™ technology, is derived from a naturally occurring material and is thus harmless to the environment, biologically inert and has been shown to be safe in humans.
US Patent Application 20140023693 - PROTECTION OF MICROBIAL CELLS FROM ACIDIC DEGRADATION
PROTECTION OF MICROBIAL CELLS FROM ACIDIC DEGRADATION
A simple cellulose sulphate based microencapsulation technology has been applied to encapsulate bacterial or other microbial cells, which produce and release digestive enzymes and thereby provides an acid resistant shelter for these microbial cells.
Surprisingly, the resulting spheres were found to provide sufficient protection for encapsulated cells from treatment with aqueous acidic solutions. Thereby the cellulose sulphate microencapsulated cells, such as probiotics are now enabled to survive passage, for example, through the stomach after consumption by a human or animal with a higher survival rate than those not within a microcapsule. After passing the stomach, these cells are delivering products produced by them, e.g. enzymes or other nutrition factors.
This technology therefore proves to be very useful in providing digestive or otherwise beneficial enzymes and/or of living microbial cells, into the lower gastrointestinal tract, where they could confer their health benefit to the host. Described is how cells are encapsulated with said material, and under which conditions the encapsulated cells survive the stomach passage and how the microbial cells or enzyme produced by said microbial cells can exit the microcapsules allowing the cells and/or the enzymes produced within the microcapsules to provide their health benefit. This technology will play an important role in the improvement of food, especially probiotic foods or the delivery of food additives to improve human and animal health and wherein these cells are still able to release their generated products e.g. enzymes and/or other nutritional factors into the surrounding environment after having been exposed to an acidic environment first.